Banco Santander S.A. Has $27.89 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Banco Santander S.A. raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 8.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,100,506 shares of the biopharmaceutical company's stock after acquiring an additional 87,714 shares during the period. Banco Santander S.A.'s holdings in Pfizer were worth $27,887,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. acquired a new stake in Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter worth approximately $28,000. North Capital Inc. acquired a new stake in shares of Pfizer during the first quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $23.49 on Friday. The stock has a 50 day moving average price of $24.36 and a 200 day moving average price of $24.58. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a market capitalization of $133.55 billion, a PE ratio of 17.02, a price-to-earnings-growth ratio of 0.84 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.82 earnings per share. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analyst Ratings Changes

Several research firms have recently weighed in on PFE. The Goldman Sachs Group raised their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Leerink Partners reduced their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Citigroup raised their price target on shares of Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Wolfe Research boosted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.